

Stock Sentiment Analysis Report

Pacific Biosciences (PACB)

Analysis Period: 2026-03-17 to 2026-04-16 (30 days)

Generated: 2026-04-16 09:59:48

Executive Summary


Sentiment analysis for Pacific Biosciences (PACB) from 2026-03-17 to 2026-04-16. Analyzed 72 items across FDA and news sources.

Sentiment Breakdown

Category	Count	Percentage
Positive	26	36.1%
Negative	16	22.2%
Neutral	30	41.7%
Total	72	100.0%

Overall Sentiment: NEUTRAL

Sentiment Trend Over Time



Key Findings

No key findings available.

Top Positive Events

Title	Source	Date	Score
DNA Sequencing Market to Expand at 18%+ CAGR by 20...	news	2026-03-20	0.735
Pacific Biosciences (PACB) upgraded to strong buy:...	alpha_vantage	2026-03-19	0.711
2025 Immunology and Immunotherapy SMRT Grant winne...	alpha_vantage	2026-03-25	0.681
PacBio Secures Agreement with Basecamp Research fo...	alpha_vantage	2026-03-27	0.670
Pacific Biosciences (PACB) Raised to Strong Buy: W...	alpha_vantage	2026-03-18	0.670

Top Negative Events

Title	Source	Date	Score
Genomic analysis of human-infecting Leptospira bor...	news	2026-03-27	-0.791
Pacific Biosciences of California unveils SPRQ-Nx ...	alpha_vantage	2026-04-09	-0.660
Powering cancer testing research with HiFi whole g...	alpha_vantage	2026-04-02	-0.660
Pacific Biosciences of California (PACB) Suffers a...	alpha_vantage	2026-04-14	-0.637
Pacific Biosciences of California expands cancer r...	alpha_vantage	2026-03-20	-0.612